Part D Plans Want A Preferred Specialty Tier, But Not The Limit To Generics And Biosimilars

Payers say Part D plans should have flexibility in determining which drugs to place on a preferred specialty tier, while manufacturers oppose the notion of a second specialty tier altogether.